Menu Search
Equities

Haleon PLC

HLN:NYQ

Haleon PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)10.61
  • Today's Change0.095 / 0.90%
  • Shares traded3.88m
  • 1 Year change+28.23%
  • Beta--
Data delayed at least 15 minutes, as of Sep 16 2024 18:20 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Haleon PLC had little change in net income (from 1.06bn to 1.05bn) despite revenues that grew 4.09% from 10.86bn to 11.30bn.
Gross margin61.56%
Net profit margin10.08%
Operating margin17.82%
Return on assets3.36%
Return on equity6.58%
Return on investment4.00%
More ▼

Cash flow in GBPView more

In 2023, Haleon PLC increased its cash reserves by 62.68%, or 383.00m. The company earned 2.10bn from its operations for a Cash Flow Margin of 18.58%. In addition the company used 134.00m on investing activities and also paid 1.57bn in financing cash flows.
Cash flow per share0.0533
Price/Cash flow per share190.70
Book value per share4.77
Tangible book value per share-2.81
More ▼

Balance sheet in GBPView more

Haleon PLC has a Debt to Total Capital ratio of 34.65%, a lower figure than the previous year's 53.30%.
Current ratio0.8375
Quick ratio0.5775
Total debt/total equity0.5336
Total debt/total capital0.3465
More ▼

Growth rates in GBP

Year on year, growth in earnings per share excluding extraordinary items dropped -1.29%.
Div yield(5 year avg)0.00%
Div growth rate (5 year)--
Payout ratio (TTM)35.66%
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		-11.55
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.